Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
|Articles|September 29, 2011
Jacob Freedman Bio
PT Blogger
Advertisement
Jacob L. Freedman, MD, is a resident in psychiatry at The Harvard Longwood Psychiatry Residency Training Program in Boston, Massachusetts.
He is a graduate of The College of William and Mary and The University of Massachusetts Medical School. He has written and lectured on a broad range of topics- spanning psychiatry, professional ethics, and Jewish history-and has also published creative fiction. His clinical interests include first episode psychosis, community psychiatry, integrated therapies, and medical education. His non-academic interests include basketball and Middle Eastern cuisine. He can be most easily reached at:
Advertisement
Related to this article
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Explore Q3 2026 psych pipeline highlights—wins, setbacks, top disorders, and breakthrough ADHD, TRD, schizophrenia and Alzheimer therapies to watch.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5